Find out how AI influences drug discovery, enabling earlier predictions and reducing the risks in clinical development.

Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to ...

On January 9, 2026, the latest edition of Applied Artificial Intelligence for Drug Discovery was published online as a Springer Nature volume, spanning 27 chapters authored by leading international ...

This figure illustrates three key applications of AI in antimicrobial drug development: (1) target identification and validation, including novel target discovery, affinity prediction, multi-target ...

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

SAN DIEGO--(BUSINESS WIRE)--Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world ...

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round. The Company ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

According to MarketsandMarkets™, the Drug Discovery Technologies Market is projected to grow from about USD 30.58 billion in ...